ARCHIMED completes acquisition of ZimVie for $19 per share in cash.

ZimVie Inc., a global life sciences leader in the dental implant market, has been acquired by ARCHIMED, an investment firm focused on healthcare industries. The acquisition, announced in July, completes with ZimVie stockholders receiving $19.00 in cash per share. The company's common stock will no longer trade on the NASDAQ stock exchange. ARCHIMED aims to support ZimVie's growth as a global leader in the dental implant market.

On October 20, 2025, ZimVie Inc. (NASDAQ: ZIMV), a global leader in the dental implant market, announced that ARCHIMED, an investment firm specializing in healthcare industries, has completed its acquisition of ZimVie. The acquisition, initially announced on July 20, 2025, saw ARCHIMED acquire all outstanding ZimVie shares for $19.00 in cash per share, according to a ZimVie press release.

Under the terms of the acquisition, ZimVie's common stock will no longer trade on the NASDAQ stock exchange. The transaction involved financial and legal advisors for both parties, with Centerview Partners serving as the exclusive financial advisor to ZimVie and Cravath, Swaine & Moore LLP as the legal advisor. UBS Investment Bank and Latham & Watkins LLP served as the exclusive financial and legal advisors to ARCHIMED, respectively, as reported in a GlobeNewswire release.

ARCHIMED, with offices in Europe, North America, and Asia, is a leading investment firm with a focus on healthcare industries. The firm's expertise spans various sectors, including Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED manages €8 billion across its funds and is committed to impact investing, according to the GlobeNewswire release.

ZimVie, headquartered in Palm Beach Gardens, Florida, and with additional facilities globally, develops, manufactures, and delivers comprehensive tooth replacement solutions. The company's portfolio includes trusted dental implants, biomaterials, and digital workflow solutions. ZimVie is dedicated to advancing clinical science and technology to improve smiles, function, and confidence in daily life, as noted in the StockTitan announcement.

The acquisition is expected to accelerate ZimVie's growth as a global leader in the dental implant market. ARCHIMED's strategic and financial partnership aims to support ZimVie's innovation and expansion efforts, according to the StockTitan announcement.